Fidia Farmaceutici announces the acquisition of 100% of the share capital of Altacor Ltd, a UK-based specialist ophthalmology company with a growing portfolio of products, including Clinitas, a dedicated line for dry eye treatment.
Marking Fidia’s direct entry into the rapidly growing UK ophthalmology market, the acquisition will expand the company’s operational footprint and strengthen its positioning in a strategically important therapeutic area.
The initiative represents a significant milestone in Fidia’s international growth strategy, which aims to create synergies in operations and distribution across high-potential markets and therapeutic segments.
The acquisition will enable Fidia to enhance Altacor’s existing portfolio and to introduce its own innovative products and treatments to the UK market.
These include a wide range of high-quality artificial tears formulated with its unique patented Fidia Hyaluronic Acid (FHA 1.0), designed to address different forms of dry eye disease, as well as diagnostic stains for ocular surface diseases, a comprehensive line of ophthalmic food supplements and multiple platforms to support cataract and corneal crosslinking surgeries.
In addition to the takeover of Altacor, Fidia also announces the acquisition of Meditrina Pharmaceuticals Srl, a Romanian company specialising in the distribution, promotion and marketing of medical devices, food supplements, pharmaceuticals and cosmetics in the areas of urology, gynaecology and dermatology.
Meditrina also operates in Moldova through its subsidiary Meditrina Pharmaceuticals Srl, Moldova.
These acquisitions form part of a broader €150m investment plan for the 2025-2026 period and mark the latest in a series of strategic international expansion initiatives.
Carlo Pizzocaro (pictured), President and CEO of Fidia Farmaceutici, stated: “Building on a series of strategic M&A operations completed in recent years, the acquisition of Altacor represents another milestone in our international growth journey."
"We are increasingly focusing our investments on high-potential markets, such as the UK, to strengthen our global presence and expand into new therapeutic areas."
"By broadening our product portfolio and gaining access to complementary channels, we will further reinforce our position as a leading international player, delivering innovative and effective solutions to meet patient needs in every country where we operate."